APA (7th ed.) Citation

Baker, D., Pryce, G., James, L. K., Marta, M., & Schmierer, K. (2020). The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Multiple sclerosis and related disorders, 44, 102279. https://doi.org/10.1016/j.msard.2020.102279

Chicago Style (17th ed.) Citation

Baker, David, Gareth Pryce, Louisa K. James, Monica Marta, and Klaus Schmierer. "The Ocrelizumab Phase II Extension Trial Suggests the Potential to Improve the Risk: Benefit Balance in Multiple Sclerosis." Multiple Sclerosis and Related Disorders 44 (2020): 102279. https://doi.org/10.1016/j.msard.2020.102279.

MLA (9th ed.) Citation

Baker, David, et al. "The Ocrelizumab Phase II Extension Trial Suggests the Potential to Improve the Risk: Benefit Balance in Multiple Sclerosis." Multiple Sclerosis and Related Disorders, vol. 44, 2020, p. 102279, https://doi.org/10.1016/j.msard.2020.102279.